No Data
Hainan Huluwa Pharmaceutical Group (605199.SH) received the administrative supervisory measures decision letter from the Hainan Securities Regulatory Bureau.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company received notification from the China Securities Regulatory Commission on March 14, 2025...
Hainan Huluwa Pharmaceutical Group (605199.SH): Lansoprazole for injection has passed the consistency evaluation for generic drugs.
On March 7, Gelonghui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) announced that it has recently received the "Approval Notice for the Supplementary Application of Pharmaceutical for Injectable Lansoprazole" issued by the National Medical Products Administration. This Pharmaceutical has passed the consistency evaluation for quality and efficacy of generic drugs. Injectable Lansoprazole is suitable for gastric and duodenal ulcers with bleeding, acute stress ulcers, and acute gastric mucosal damage when oral therapy is not applicable.
Former TJ DaRenTang Chairman Zhang Mingrui has taken over as General Manager of Hainan Huluwa Pharmaceutical Group, responsible for the company's overall Operation work | Quick read announcement
① Former TJ DaRenTang Chairman Zhang Mingrui has been appointed General Manager of Hainan Huluwa Pharmaceutical Group. Company sources indicate, "Chairman Liu Jingping will primarily focus on the work related to the Board of Directors in the future, while General Manager Zhang Mingrui will be responsible for the company's overall Operation." ② Company sources also noted that this year marks the year of Hainan's customs closure, and the company is facing significant opportunities for strategic development. The company's invitation for Mr. Zhang is also strategical.
Hainan Huluwa Pharmaceutical Group (605199.SH): Appointed Zhang Mingrui as the company's general manager.
On March 4, Gelonghui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the Board of Directors recently received a resignation letter submitted by Ms. Liu Jingping. In order to better fulfill the duties of the chairman and devote more energy to the company's strategic planning and governance, Ms. Liu Jingping applied to resign from the position of general manager. After her resignation as general manager, Ms. Liu Jingping will continue to serve as the company's chairman, head of the Strategic and ESG Committee, and a member of the Nomination Committee. Ms. Liu Jingping's resignation letter will take effect from the date it is delivered to the Board of Directors, and her resignation will not adversely affect the company's daily Operations. The company will be on March 2025.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Hainan Huluwa Pharmaceutical Group (605199.SH): Obtained the registration certificate for Pharmaceutical soft capsules of calcitriol.
On February 28, Gelonghui reported that Hainan Huluwa Pharmaceutical Group (605199.SH) recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for calcifediol soft capsules. The indications for calcifediol soft capsules include: 1. Postmenopausal osteoporosis; 2. Chronic kidney failure, especially in patients undergoing hemodialysis with renal osteodystrophy; 3. Postoperative hypoparathyroidism; 4. Idiopathic hypoparathyroidism; 5. Pseudohypoparathyroidism; 6. Vitamin D-dependent rickets; 7. Hypophosphatemic vitamin D-resistant rickets, etc.
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
